AARTI DRUGS LIMITED

Scale -

PAT is 195 Rs Cr; Annual Growth is 16 %
Quarterly Ebitda is 98.2 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
Revenue is 2565 Rs Cr; in Top Quartile
Quarterly Revenue is 703 Rs Cr; in Top Quartile

Profitability -

PAT Margin is 7.59 %; Continuous Growth over 3 years
Quarterly Ebitda Margin is 14 %; Continuous Growth over 3 Quarters

Return -

Asset Turnover is 95 %; in Top Quartile

ROCE is 12.92 %; Continuous Decline over 3 years

Efficiency -

Inventory Turnover Ratio is 5.32; Continuous Growth over 3 years; in Top Quartile
Operating cash flow is 254 Rs Cr; 5 Year CAGR is 38 %

Current Ratio is 1.59; Continuous Decline over 3 years

Solvancy -

Contingent Liabilities is 367 Rs Cr; Continuous Growth over 3 years; in Top Quartile
Debt/Equity is 0.37; in Top Quartile
Long term Debt is 257 Rs Cr; in Top Quartile
Total Debt is 575 Rs Cr; in Top Quartile

Quality -

Current Tax/PAT is 23 %; Annual Decline is -26 %; Continuous Decline over 3 years
Change in Inventories/Total Expenses is 0 %; Annual Decline is -102 %; Continuous Decline over 3 years
Operating cashflow/ebitda is 81 %; in Top Quartile; 5 Year CAGR is 41 %
Other Expenses/Total Expenses is 5 %; in Bottom Quartile; Continuous Growth over 3 years
Operating cashflow/PAT is 130 %; 5 Year CAGR is 40 %; Continuous Decline over 3 years

Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector

Major Subsidiaries/Associates

Key Clients

Products

Products

Product details

Operations

Capacity/ Production

Key Facilities

Key Certifications

Raw materials

Search: